drugset / Trial / NCT03379649

Platelet Rich Plasma for Patients With Recurrent Implantation Failure

NCT03379649

Phase 0 Completed 50 enrolled Stanford University
RandomizedParallel-groupSingle-blindTreatment

Summary

Patients with recurrent implantation failure are among the most difficult patients to treat, with no proven standard treatment. Platelet rich plasma stimulates cellular processes involved in endometrial regeneration, and in a small case series has shown efficacy for this patient population. We hope to conduct a randomized controlled pilot study to determine whether PRP is indeed an effective treatment for recurrent implantation failure.

Timeline

Start
2019-01-16
Primary completion
2023-12-20
Completion
2023-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Platelet Rich Plasma Other / unclassified 0.5 ml Other

Indications